TY - JOUR
T1 - The impact of cancer metastases on COVID-19 outcomes
T2 - A COVID-19 and Cancer Consortium registry-based retrospective cohort study
AU - Castellano, Cecilia A.
AU - Sun, Tianyi
AU - Ravindranathan, Deepak
AU - Hwang, Clara
AU - Balanchivadze, Nino
AU - Singh, Sunny R.K.
AU - Griffiths, Elizabeth A.
AU - Puzanov, Igor
AU - Ruiz-Garcia, Erika
AU - Vilar-Compte, Diana
AU - Cárdenas-Delgado, Ana I.
AU - McKay, Rana R.
AU - Nonato, Taylor K.
AU - Ajmera, Archana
AU - Yu, Peter P.
AU - Nadkarni, Rajani
AU - O’Connor, Timothy E.
AU - Berg, Stephanie
AU - Ma, Kim
AU - Farmakiotis, Dimitrios
AU - Vieira, Kendra
AU - Arvanitis, Panos
AU - Saliby, Renee M.
AU - Labaki, Chris
AU - El Zarif, Talal
AU - Wise-Draper, Trisha M.
AU - Zamulko, Olga
AU - Li, Ningjing
AU - Bodin, Brianne E.
AU - Accordino, Melissa K.
AU - Ingham, Matthew
AU - Joshi, Monika
AU - Polimera, Hyma V.
AU - Fecher, Leslie A.
AU - Friese, Christopher R.
AU - Yoon, James J.
AU - Mavromatis, Blanche H.
AU - Brown, Jacqueline T.
AU - Russell, Karen
AU - Nanchal, Rahul
AU - Singh, Harpreet
AU - Tachiki, Lisa
AU - Moria, Feras A.
AU - Nagaraj, Gayathri
AU - Cortez, Kimberly
AU - Abbasi, Saqib H.
AU - Wulff-Burchfield, Elizabeth M.
AU - Puc, Matthew
AU - Weissmann, Lisa B.
AU - Bhatt, Padmanabh S.
AU - Mariano, Melissa G.
AU - Mishra, Sanjay
AU - Halabi, Susan
AU - Beeghly, Alicia
AU - Warner, Jeremy L.
AU - French, Benjamin
AU - Bilen, Mehmet A.
N1 - Publisher Copyright:
© 2024 American Cancer Society.
PY - 2024/6/15
Y1 - 2024/6/15
N2 - Background: COVID-19 can have a particularly detrimental effect on patients with cancer, but no studies to date have examined if the presence, or site, of metastatic cancer is related to COVID-19 outcomes. Methods: Using the COVID-19 and Cancer Consortium (CCC19) registry, the authors identified 10,065 patients with COVID-19 and cancer (2325 with and 7740 without metastasis at the time of COVID-19 diagnosis). The primary ordinal outcome was COVID-19 severity: not hospitalized, hospitalized but did not receive supplemental O2, hospitalized and received supplemental O2, admitted to an intensive care unit, received mechanical ventilation, or died from any cause. The authors used ordinal logistic regression models to compare COVID-19 severity by presence and specific site of metastatic cancer. They used logistic regression models to assess 30-day all-cause mortality. Results: Compared to patients without metastasis, patients with metastases have increased hospitalization rates (59% vs. 49%) and higher 30 day mortality (18% vs. 9%). Patients with metastasis to bone, lung, liver, lymph nodes, and brain have significantly higher COVID-19 severity (adjusted odds ratios [ORs], 1.38, 1.59, 1.38, 1.00, and 2.21) compared to patients without metastases at those sites. Patients with metastasis to the lung have significantly higher odds of 30-day mortality (adjusted OR, 1.53; 95% confidence interval, 1.17–2.00) when adjusting for COVID-19 severity. Conclusions: Patients with metastatic cancer, especially with metastasis to the brain, are more likely to have severe outcomes after COVID-19 whereas patients with metastasis to the lung, compared to patients with cancer metastasis to other sites, have the highest 30-day mortality after COVID-19.
AB - Background: COVID-19 can have a particularly detrimental effect on patients with cancer, but no studies to date have examined if the presence, or site, of metastatic cancer is related to COVID-19 outcomes. Methods: Using the COVID-19 and Cancer Consortium (CCC19) registry, the authors identified 10,065 patients with COVID-19 and cancer (2325 with and 7740 without metastasis at the time of COVID-19 diagnosis). The primary ordinal outcome was COVID-19 severity: not hospitalized, hospitalized but did not receive supplemental O2, hospitalized and received supplemental O2, admitted to an intensive care unit, received mechanical ventilation, or died from any cause. The authors used ordinal logistic regression models to compare COVID-19 severity by presence and specific site of metastatic cancer. They used logistic regression models to assess 30-day all-cause mortality. Results: Compared to patients without metastasis, patients with metastases have increased hospitalization rates (59% vs. 49%) and higher 30 day mortality (18% vs. 9%). Patients with metastasis to bone, lung, liver, lymph nodes, and brain have significantly higher COVID-19 severity (adjusted odds ratios [ORs], 1.38, 1.59, 1.38, 1.00, and 2.21) compared to patients without metastases at those sites. Patients with metastasis to the lung have significantly higher odds of 30-day mortality (adjusted OR, 1.53; 95% confidence interval, 1.17–2.00) when adjusting for COVID-19 severity. Conclusions: Patients with metastatic cancer, especially with metastasis to the brain, are more likely to have severe outcomes after COVID-19 whereas patients with metastasis to the lung, compared to patients with cancer metastasis to other sites, have the highest 30-day mortality after COVID-19.
KW - COVID-19
KW - cancer
KW - metastasis
UR - https://www.scopus.com/pages/publications/85186240405
U2 - 10.1002/cncr.35247
DO - 10.1002/cncr.35247
M3 - Article
C2 - 38376917
AN - SCOPUS:85186240405
SN - 0008-543X
VL - 130
SP - 2191
EP - 2204
JO - Cancer
JF - Cancer
IS - 12
ER -